Global Non-alcoholic Steatohepatitis Market 2016-2020 - Limited Understanding of Disease Pathophysiology - Research and Markets

News provided by

Research and Markets

20 May, 2016, 12:10 GMT

DUBLIN, May 20, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Non-alcoholic Steatohepatitis Market 2016-2020" report to their offering.

The global NASH market is set to grow at a CAGR of 24.58% during the period 2016-2020.

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis.

One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.

According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.

Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease's pathophysiology.

Key vendors:

  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by dosage form

PART 09: Market segmentation by route of administration

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/mnsws6/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com